Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 8/20 | 0.49 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095964 | 1.00 | FUCA1 (0.50) | FUCA1KDM1AMAOAMAOBFYN | |
| SCHEMBL2301167 | 0.76 | GRIN2B (0.56) | KDM1AMAOAFYNGRIN2B | |
| SCHEMBL9033727 | 0.76 | KDM1A (0.45) | FUCA1KDM1AMAOAMAOBGRIN2B | |
| SCHEMBL14001426 | 0.74 | LTA4H (0.58) | FUCA1KDM1AMAOAGRIN2B | |
| SCHEMBL697761 | 0.74 | LTA4H (0.58) | FUCA1KDM1AMAOAGRIN2B | |
| SCHEMBL1755583 | 0.74 | LTA4H (0.58) | FUCA1KDM1AMAOAGRIN2B | |
| SCHEMBL15818134 | 0.74 | LTA4H (0.58) | FUCA1KDM1AMAOAFYNGRIN2B | |
| SCHEMBL15780394 | 0.74 | LTA4H (0.58) | FUCA1KDM1AMAOAGRIN2B | |
| SCHEMBL15921601 | 0.74 | LTA4H (0.58) | FUCA1KDM1AMAOAGRIN2B | |
| SCHEMBL13634413 | 0.74 | LTA4H (0.58) | FUCA1KDM1AMAOAFYNGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | claimed |
| US-8163769-B2 | 1,8-naphthyridine derivatives | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| US-20030232818-A1 | Antibacterial compounds | ABBVIE INC. | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232818-A1 | Antibacterial compounds | PGLS, UGT1A1, CASP1 | FUCA1 1697/4885KDM1A 2856/4885MAOA 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.